These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 30934169

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT, Liao HI, Wu Lin FL, Chang SC.
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [Abstract] [Full Text] [Related]

  • 23. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication.
    Kanazawa N, Matsumoto K, Ikawa K, Fukamizu T, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K.
    J Infect Chemother; 2011 Apr; 17(2):297-300. PubMed ID: 20714913
    [Abstract] [Full Text] [Related]

  • 24. Higher Teicoplanin Blood Level Needed in Elderly Critically Ill Patients.
    Wang L, Chen M, Ye H, Lin X, Li Y, Ruan J, Lin F, Lin Y.
    Curr Drug Metab; 2021 Apr; 22(14):1124-1131. PubMed ID: 34809542
    [Abstract] [Full Text] [Related]

  • 25. Influence of arterio-venous haemofiltration on teicoplanin elimination.
    Hillaire-Buys D, Peyriere H, Lobjoie E, Bres J, Ossart M, Despaux E.
    Br J Clin Pharmacol; 1995 Jul; 40(1):95-7. PubMed ID: 8527277
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.
    Wi J, Noh H, Min KL, Yang S, Jin BH, Hahn J, Bae SK, Kim J, Park MS, Choi D, Chang MJ.
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674057
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Level of evidence for therapeutic drug monitoring of teicoplatin].
    Boulamery A, Venisse N, Le Guellec C, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.
    Therapie; 2011 Sep; 66(1):45-50. PubMed ID: 21466777
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.
    Matthews PC, Chue AL, Wyllie D, Barnett A, Isinkaye T, Jefferies L, Lovering A, Scarborough M.
    J Infect; 2014 Jan; 68(1):43-9. PubMed ID: 24012820
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function.
    Derbyshire N, Webb DB, Roberts D, Glew D, Williams JD.
    J Antimicrob Chemother; 1989 Jun; 23(6):869-76. PubMed ID: 2527223
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients.
    Aulin LBS, De Paepe P, Dhont E, de Jaeger A, Vande Walle J, Vandenberghe W, McWhinney BC, Ungerer JPJ, van Hasselt JGC, De Cock PAJG.
    Clin Pharmacokinet; 2021 Mar; 60(3):353-363. PubMed ID: 33030704
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.